This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 2.70% and 1.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
OPCH or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OPCH vs. USPH: Which Stock Is the Better Value Option?
U.S. Physical Therapy (USPH) Surges 3.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
U.S. Physical Therapy (USPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
U.S. Physical Therapy (USPH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 13.46% and 6.19%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Chemed (CHE) Q1 Earnings Lag Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -2.03% and 2.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Encompass Health (EHC) Soars 11.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Encompass Health (EHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
U.S. Physical Therapy (USPH) Soars 3.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
U.S. Physical Therapy (USPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
U.S. Physical Therapy (USPH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 5.45% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 1.08% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Will ATI Physical Therapy, Inc. (ATIP) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita HealthCare (DVA) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -12.12% and 1.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Option Care (OPCH) Q3 Earnings Match Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 0% and 2.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -3.23% and 1.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Oak Street Health, Inc. (OSH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oak Street Health, Inc. (OSH) delivered earnings and revenue surprises of -34.69% and 0.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Adherex Technologies (FENC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.
DaVita HealthCare (DVA) Surges 6%: Is This an Indication of Further Gains?
by Zacks Equity Research
DaVita HealthCare (DVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
3 Stocks to Watch From a Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic-induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.
U.S. Physical Therapy (USPH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 3.17% and 1.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: U.S. Physical Therapy (USPH) Q1 Earnings Expected to Decline
by Zacks Equity Research
U.S. Physical Therapy (USPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.